Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Kemurnian >98,0% (HPLC) Lenvatinib Mesylate Intermediate Factory

Katrangan singkat:

Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate

CAS: 205448-66-4

Kemurnian: >98,0% (HPLC)

Penampilan: Putih-putih nganti bubuk padat kuning

Penengah saka Lenvatinib Mesylate CAS 857890-39-2

Kualitas Tinggi, Produksi Komersial

E-Mail: alvin@ruifuchem.com


Detail Produk

Produk sing gegandhengan

Tag produk

katrangan:

Sifat Kimia:

Jeneng Kimia Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate
sinonim Lenvatinib Impurity 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Acid Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acid Methyl Ester;Lenvaint-D
Nomer CAS 205448-66-4
Nomer CAT RF-PI1970
Status Simpenan Ing Simpenan, Skala Produksi Nganti Ton
Formula Molekul C12H10ClNO3
Bobot Molekul 251.67
Titik didih 377,4 ± 37,0 ℃
Kapadhetan 1,320±0,06 g/cm3
Merk Kimia Ruifu

Spesifikasi:

Item Spesifikasi
Penampilan Bubuk Padhet Putih nganti Kuning
1 H NMR Spektrum Konsisten karo Struktur
Kemurnian / Metode Analisis > 98,0% (HPLC)
Mundhut ing Pangatusan <1.00%
Total Impurities <2.00%
Test Standar Standar Perusahaan
Panggunaan Intermediate/Impurity saka Lenvatinib Mesylate (CAS: 857890-39-2)

Paket & Panyimpenan:

Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan

Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan

Kaluwihan:

1

FAQ:

Aplikasi:

Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (CAS: 205448-66-4) minangka perantara saka Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib minangka obat kanker tiroid sing dikembangake dening Eisai Corporation of Japan (Kode: E7080), kagolong ing inhibitor multi-reseptor tyrosine kinase (RTK) lisan lan bisa nyandhet aktivitas kinase saka faktor pertumbuhan endothelial vaskular Reseptor R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4).Lenvatinib uga bisa nyandhet keterlibatan RTK liyane ing angiogenesis patologis, pertumbuhan tumor, lan perkembangan kanker kajaba fungsi seluler normal kalebu reseptor faktor pertumbuhan fibroblast (FGF) FGFR1, 2, 3, lan 4;platelet-derived growth factor receptor (PDGFR [alpha]), KIT, lan RET.[Indikasi]: Lenvatinib cocok kanggo perawatan pasien kanker tiroid saka jinis kambuh utawa metastasis lokal, jinis progresif lan jinis diferensiasi yodium-refraktori radioaktif.

Tulis pesen sampeyan ing kene lan kirimake menyang kita